Skip to main content
. 2023 Jul 17;11:1223191. doi: 10.3389/fped.2023.1223191

Table 1.

Investigations on presentation.

Investigation Result Normal range
Blood profile
Hemoglobin (g/dl) 9.1 11–13.7
Hematocrit (%) 29.7 34–44
Total WBC count (cells/µl) 7,180 4,500–13,500
Differential WBC count (%)
 Neutrophil/band  Lymphocyte  Eosinophil  Basophil  Monocyte 8.8 44.2 0.9 1.8 44.2 55–70 20–40 1–4 0.5–1 2–8
Absolute neutrophil count (cells/µl) 630 1,800–8,000
Platelet count (x109 cells/L) 128 150–450
PT (sec) 18.1 12.1–14.6
PTT (sec) 31.9 25.0–37.0
INR 1.45 0.92–1.14
Fibrinogen (mg/dl) 398 200–400
Functional antithrombin (%) 71 80–120
ESR (mm/h) 23 0–10
Urine analysis
Glucose Normal
Blood Negative
Protein Negative
Ketone Negative
Bilirubin Negative
Liver function tests
Total bilirubin (mg/dl) 0.2 0.1–1.2
Direct bilirubin (mg/dl) <0.2 <0.3
Aspartate transaminase (U/L) 29 10–40
Alanine transaminase (U/L) 10 10–40
Alkaline phosphatase (U/L) 225 130–260
Renal function tests
Creatinine (mg/dl) 0.23 0.44–0.65
BUN (mg/dl) 8 5–18
Inflammatory markers
C-reactive protein (mg/dl) 4.51 <0.9
Microbiology/virology
Blood cultures No growth
MRSA surveillance cultures Negative
Respiratory pathogen testsa Negative
Coagulation profile from 2018b
Platelets (x103 cells/µl) 108 223–461
PT (sec) 15.4 12.1–14.6
INR 1.19
PTT (sec) 37.5 25.0–37.0
Thrombin time (sec) 15.7 14.4–18.0
Fibrinogen (mg/dl) 267 200–400
Factor II activity (%) 50 50–150
Factor V activity (%) 77 50–150
Factor VII activity (%) 66 50–150
Factor XII activity (%) 98 69–143
PTT inhibitor screen Negative
PT inhibitor screen Negative
Lupus anticoagulant screen Negative
vWF Risto Cofactor (%) 63 50–150
vWF Antigen (%) 83 50–160
vWF VIII (%) 79 70–170

WBC, white blood cells; PT, prothrombin time; PTT, partial thromboplastin time; INR, international normalized ratio; ESR, erythrocyte sedimentation rate; BUN, blood urea nitrogen; vWF, von Willebrand Factor.

Values outside the normal range are in bold.

a

Negative respiratory pathogen PCR tests for adenovirus, SARS-CoV-2, influenza A, influenza B, human metapneumovirus, parainfluenza 1, parainfluenza 2, parainfluenza 3, parainfluenza 4, respiratory syncytial virus, and rhinovirus.

b

After the second bleeding event.